Research Area: Cellular & Molecular Neuroscience

​synapses, vesicles, electrophysiology, protein complexes, signaling, small molecules, disease-linked genes, dendrites, cell death, brain disorders, neurodevelopment

How the brain generates rhythmic behavior

Anne Trafton |

Many of our bodily functions, such as walking, breathing, and chewing, are controlled by brain circuits called central oscillators, which generate rhythmic firing patterns that regulate these behaviors.

MIT neuroscientists have now discovered the neuronal identity and mechanism underlying one of these circuits: an oscillator that controls the rhythmic back-and-forth sweeping of tactile whiskers, or whisking, in mice. This is the first time that any such oscillator has been fully characterized in mammals.

The MIT team found that the whisking oscillator consists of a population of inhibitory neurons in the brainstem that fires rhythmic bursts during whisking. As each neuron fires, it also inhibits some of the other neurons in the network, allowing the overall population to generate a synchronous rhythm that retracts the whiskers from their protracted positions.

“We have defined a mammalian oscillator molecularly, electrophysiologically, functionally, and mechanistically,” says Fan Wang, an MIT professor of brain and cognitive sciences and a member of MIT’s McGovern Institute for Brain Research. “It’s very exciting to see a clearly defined circuit and mechanism of how rhythm is generated in a mammal.”

Wang is the senior author of the study, which appears today in Nature. The lead authors of the paper are MIT research scientists Jun Takatoh and Vincent Prevosto.

Rhythmic behavior

Most of the research that clearly identified central oscillator circuits has been done in invertebrates. For example, Eve Marder’s lab at Brandeis University found cells in the stomatogastric ganglion in lobsters and crabs that generate oscillatory activity to control rhythmic motion of the digestive tract.

Characterizing oscillators in mammals, especially in awake behaving animals, has proven to be highly challenging. The oscillator that controls walking is believed to be distributed throughout the spinal cord, making it difficult to precisely identify the neurons and circuits involved. The oscillator that generates rhythmic breathing is located in a part of the brain stem called the pre-Bötzinger complex, but the exact identity of the oscillator neurons is not fully understood.

“There haven’t been detailed studies in awake behaving animals, where one can record from molecularly identified oscillator cells and manipulate them in a precise way,” Wang says.

Whisking is a prominent rhythmic exploratory behavior in many mammals, which use their tactile whiskers to detect objects and sense textures. In mice, whiskers extend and retract at a frequency of about 12 cycles per second. Several years ago, Wang’s lab set out try to identify the cells and the mechanism that control this oscillation.

To find the location of the whisking oscillator, the researchers traced back from the motor neurons that innervate whisker muscles. Using a modified rabies virus that infects axons, the researchers were able to label a group of cells presynaptic to these motor neurons in a part of the brainstem called the vibrissa intermediate reticular nucleus (vIRt). This finding was consistent with previous studies showing that damage to this part of the brain eliminates whisking.

The researchers then found that about half of these vIRt neurons express a protein called parvalbumin, and that this subpopulation of cells drives the rhythmic motion of the whiskers. When these neurons are silenced, whisking activity is abolished.

Next, the researchers recorded electrical activity from these parvalbumin-expressing vIRt neurons in brainstem in awake mice, a technically challenging task, and found that these neurons indeed have bursts of activity only during the whisker retraction period. Because these neurons provide inhibitory synaptic inputs to whisker motor neurons, it follows that rhythmic whisking is generated by a constant motor neuron protraction signal interrupted by the rhythmic retraction signal from these oscillator cells.

“That was a super satisfying and rewarding moment, to see that these cells are indeed the oscillator cells, because they fire rhythmically, they fire in the retraction phase, and they’re inhibitory neurons,” Wang says.

A maximum projection image showing tracked whiskers on the mouse muzzle. The right (control) side shows the back-and-forth rhythmic sweeping of the whiskers, while the experimental side where the whisking oscillator neurons are silenced, the whiskers move very little. Image: Wang Lab

“New principles”

The oscillatory bursting pattern of vIRt cells is initiated at the start of whisking. When the whiskers are not moving, these neurons fire continuously. When the researchers blocked vIRt neurons from inhibiting each other, the rhythm disappeared, and instead the oscillator neurons simply increased their rate of continuous firing.

This type of network, known as recurrent inhibitory network, differs from the types of oscillators that have been seen in the stomatogastric neurons in lobsters, in which neurons intrinsically generate their own rhythm.

“Now we have found a mammalian network oscillator that is formed by all inhibitory neurons,” Wang says.

The MIT scientists also collaborated with a team of theorists led by David Golomb at Ben-Gurion University, Israel, and David Kleinfeld at the University of California at San Diego. The theorists created a detailed computational model outlining how whisking is controlled, which fits well with all experimental data. A paper describing that model is appearing in an upcoming issue of Neuron.

Wang’s lab now plans to investigate other types of oscillatory circuits in mice, including those that control chewing and licking.

“We are very excited to find oscillators of these feeding behaviors and compare and contrast to the whisking oscillator, because they are all in the brain stem, and we want to know whether there’s some common theme or if there are many different ways to generate oscillators,” she says.

The research was funded by the National Institutes of Health.

Microscopy technique reveals hidden nanostructures in cells and tissues

Anne Trafton |

Press Mentions

Making the invisible visible

The Economist

Inside a living cell, proteins and other molecules are often tightly packed together. These dense clusters can be difficult to image because the fluorescent labels used to make them visible can’t wedge themselves in between the molecules.

MIT researchers have now developed a novel way to overcome this limitation and make those “invisible” molecules visible. Their technique allows them to “de-crowd” the molecules by expanding a cell or tissue sample before labeling the molecules, which makes the molecules more accessible to fluorescent tags.

This method, which builds on a widely used technique known as expansion microscopy previously developed at MIT, should allow scientists to visualize molecules and cellular structures that have never been seen before.

“It’s becoming clear that the expansion process will reveal many new biological discoveries. If biologists and clinicians have been studying a protein in the brain or another biological specimen, and they’re labeling it the regular way, they might be missing entire categories of phenomena,” says Edward Boyden, the Y. Eva Tan Professor in Neurotechnology, a professor of biological engineering and brain and cognitive sciences at MIT, a Howard Hughes Medical Institute investigator, and a member of MIT’s McGovern Institute for Brain Research and Koch Institute for Integrative Cancer Research.

Using this technique, Boyden and his colleagues showed that they could image a nanostructure found in the synapses of neurons. They also imaged the structure of Alzheimer’s-linked amyloid beta plaques in greater detail than has been possible before.

“Our technology, which we named expansion revealing, enables visualization of these nanostructures, which previously remained hidden, using hardware easily available in academic labs,” says Deblina Sarkar, an assistant professor in the Media Lab and one of the lead authors of the study.

The senior authors of the study are Boyden; Li-Huei Tsai, director of MIT’s Picower Institute for Learning and Memory; and Thomas Blanpied, a professor of physiology at the University of Maryland. Other lead authors include Jinyoung Kang, an MIT postdoc, and Asmamaw Wassie, a recent MIT PhD recipient. The study appears today in Nature Biomedical Engineering.

De-crowding

Imaging a specific protein or other molecule inside a cell requires labeling it with a fluorescent tag carried by an antibody that binds to the target. Antibodies are about 10 nanometers long, while typical cellular proteins are usually about 2 to 5 nanometers in diameter, so if the target proteins are too densely packed, the antibodies can’t get to them.

This has been an obstacle to traditional imaging and also to the original version of expansion microscopy, which Boyden first developed in 2015. In the original version of expansion microscopy, researchers attached fluorescent labels to molecules of interest before they expanded the tissue. The labeling was done first, in part because the researchers had to use an enzyme to chop up proteins in the sample so the tissue could be expanded. This meant that the proteins couldn’t be labeled after the tissue was expanded.

To overcome that obstacle, the researchers had to find a way to expand the tissue while leaving the proteins intact. They used heat instead of enzymes to soften the tissue, allowing the tissue to expand 20-fold without being destroyed. Then, the separated proteins could be labeled with fluorescent tags after expansion.

With so many more proteins accessible for labeling, the researchers were able to identify tiny cellular structures within synapses, the connections between neurons that are densely packed with proteins. They labeled and imaged seven different synaptic proteins, which allowed them to visualize, in detail, “nanocolumns” consisting of calcium channels aligned with other synaptic proteins. These nanocolumns, which are believed to help make synaptic communication more efficient, were first discovered by Blanpied’s lab in 2016.

“This technology can be used to answer a lot of biological questions about dysfunction in synaptic proteins, which are involved in neurodegenerative diseases,” Kang says. “Until now there has been no tool to visualize synapses very well.”

New patterns

The researchers also used their new technique to image beta amyloid, a peptide that forms plaques in the brains of Alzheimer’s patients. Using brain tissue from mice, the researchers found that amyloid beta forms periodic nanoclusters, which had not been seen before. These clusters of amyloid beta also include potassium channels. The researchers also found amyloid beta molecules that formed helical structures along axons.

“In this paper, we don’t speculate as to what that biology might mean, but we show that it exists. That is just one example of the new patterns that we can see,” says Margaret Schroeder, an MIT graduate student who is also an author of the paper.

Sarkar says that she is fascinated by the nanoscale biomolecular patterns that this technology unveils. “With a background in nanoelectronics, I have developed electronic chips that require extremely precise alignment, in the nanofab. But when I see that in our brain Mother Nature has arranged biomolecules with such nanoscale precision, that really blows my mind,” she says.

Boyden and his group members are now working with other labs to study cellular structures such as protein aggregates linked to Parkinson’s and other diseases. In other projects, they are studying pathogens that infect cells and molecules that are involved in aging in the brain. Preliminary results from these studies have also revealed novel structures, Boyden says.

“Time and time again, you see things that are truly shocking,” he says. “It shows us how much we are missing with classical unexpanded staining.”

The researchers are also working on modifying the technique so they can image up to 20 proteins at a time. They are also working on adapting their process so that it can be used on human tissue samples.

Sarkar and her team, on the other hand, are developing tiny wirelessly powered nanoelectronic devices which could be distributed in the brain. They plan to integrate these devices with expansion revealing. “This can combine the intelligence of nanoelectronics with the nanoscopy prowess of expansion technology, for an integrated functional and structural understanding of the brain,” Sarkar says.

The research was funded by the National Institutes of Health, the National Science Foundation, the Ludwig Family Foundation, the JPB Foundation, the Open Philanthropy Project, John Doerr, Lisa Yang and the Tan-Yang Center for Autism Research at MIT, the U.S. Army Research Office, Charles Hieken, Tom Stocky, Kathleen Octavio, Lore McGovern, Good Ventures, and HHMI.

McGovern Fellows recognized with life sciences innovation award

by Julie Pryor |

McGovern Institute Fellows Omar Abudayyeh and Jonathan Gootenberg have been named the inaugural recipients of the Termeer Scholars Awards, which recognize “emerging biomedical researchers that represent the future of the biotechnology industry.” The Termeer Foundation is a nonprofit organization focused on connecting life science innovators and catalyzing the creation of new medicines.

“The Termeer Foundation is committed to championing emerging biotechnology leaders and finding people who want to solve the biggest problems in human health,” said Belinda Termeer, president of the Termeer Foundation. “By supporting researchers like Omar and Jonathan, we plant the seeds for future success in individuals who are preparing to make significant contributions in academia and industry.”

The Abudayyeh-Gootenberg lab is developing a suite of new tools to enable next-generation cellular engineering, with uses in basic research, therapeutics and diagnostics. Building off the revolutionary biology of natural biological systems, including mobile genetic elements and CRISPR systems, the team develops new approaches for understanding and manipulating genomes, transcriptomes and cellular fate. The technologies have broad applications, including in oncology, aging and genetic disease.

These tools have been adopted by researchers over the world and formed the basis for four companies that Abudayyeh and Gootenberg have co-founded. They will receive a $50,000 grant to support professional development, knowledge advancement and/or stakeholder engagement and will become part of The Termeer Foundation’s signature Network of Termeer Fellows (first-time CEOs and entrepreneurs) and Mentors (experienced industry leaders).

“The Termeer Foundation is working to improve the long odds of biotechnology by identifying and supporting future biotech leaders; if we help them succeed as leaders, we can help their innovations reach patients,” said Alan Waltws, co-founder of the Termeer Foundation. “While our Termeer Fellows program has supported first time CEOs and entrepreneurs for the past five years, our new Termeer Scholars program will provide much needed support to the researchers whose innovative ideas represent the future of the biotechnology industry – researchers like Omar and Jonathan.”

Abudayyeh and Gootenberg were honored at the Termeer Foundation’s annual dinner in Boston on June 16, 2022.

Three distinct brain circuits in the thalamus contribute to Parkinson’s symptoms

Anne Trafton |

Parkinson’s disease is best-known as a disorder of movement. Patients often experience tremors, loss of balance, and difficulty initiating movement. The disease also has lesser-known symptoms that are nonmotor, including depression.

In a study of a small region of the thalamus, MIT neuroscientists have now identified three distinct circuits that influence the development of both motor and nonmotor symptoms of Parkinson’s. Furthermore, they found that by manipulating these circuits, they could reverse Parkinson’s symptoms in mice.

The findings suggest that those circuits could be good targets for new drugs that could help combat many of the symptoms of Parkinson’s disease, the researchers say.

“We know that the thalamus is important in Parkinson’s disease, but a key question is how can you put together a circuit that that can explain many different things happening in Parkinson’s disease. Understanding different symptoms at a circuit level can help guide us in the development of better therapeutics,” says Guoping Feng, the James W. and Patricia T. Poitras Professor in Brain and Cognitive Sciences at MIT, a member of the Broad Institute of Harvard and MIT, and the associate director of the McGovern Institute for Brain Research at MIT.

Feng is the senior author of the study, which appears today in Nature. Ying Zhang, a J. Douglas Tan Postdoctoral Fellow at the McGovern Institute, and Dheeraj Roy, a NIH K99 Awardee and a McGovern Fellow at the Broad Institute, are the lead authors of the paper.

Tracing circuits

The thalamus consists of several different regions that perform a variety of functions. Many of these, including the parafascicular (PF) thalamus, help to control movement. Degeneration of these structures is often seen in patients with Parkinson’s disease, which is thought to contribute to their motor symptoms.

In this study, the MIT team set out to try to trace how the PF thalamus is connected to other brain regions, in hopes of learning more about its functions. They found that neurons of the PF thalamus project to three different parts of the basal ganglia, a cluster of structures involved in motor control and other functions: the caudate putamen (CPu), the subthalamic nucleus (STN), and the nucleus accumbens (NAc).

“We started with showing these different circuits, and we demonstrated that they’re mostly nonoverlapping, which strongly suggests that they have distinct functions,” Roy says.

Further studies revealed those functions. The circuit that projects to the CPu appears to be involved in general locomotion, and functions to dampen movement. When the researchers inhibited this circuit, mice spent more time moving around the cage they were in.

The circuit that extends into the STN, on the other hand, is important for motor learning — the ability to learn a new motor skill through practice. The researchers found that this circuit is necessary for a task in which the mice learn to balance on a rod that spins with increasing speed.

Lastly, the researchers found that, unlike the others, the circuit that connects the PF thalamus to the NAc is not involved in motor activity. Instead, it appears to be linked to motivation. Inhibiting this circuit generates depression-like behaviors in healthy mice, and they will no longer seek a reward such as sugar water.

Druggable targets

Once the researchers established the functions of these three circuits, they decided to explore how they might be affected in Parkinson’s disease. To do that, they used a mouse model of Parkinson’s, in which dopamine-producing neurons in the midbrain are lost.

They found that in this Parkinson’s model, the connection between the PF thalamus and the CPu was enhanced, and that this led to a decrease in overall movement. Additionally, the connections from the PF thalamus to the STN were weakened, which made it more difficult for the mice to learn the accelerating rod task.

Lastly, the researchers showed that in the Parkinson’s model, connections from the PF thalamus to the NAc were also interrupted, and that this led to depression-like symptoms in the mice, including loss of motivation.

Using chemogenetics or optogenetics, which allows them to control neuronal activity with a drug or light, the researchers found that they could manipulate each of these three circuits and in doing so, reverse each set of Parkinson’s symptoms. Then, they decided to look for molecular targets that might be “druggable,” and found that each of the three PF thalamus regions have cells that express different types of cholinergic receptors, which are activated by the neurotransmitter acetylcholine. By blocking or activating those receptors, depending on the circuit, they were also able to reverse the Parkinson’s symptoms.

“We found three distinct cholinergic receptors that can be expressed in these three different PF circuits, and if we use antagonists or agonists to modulate these three different PF populations, we can rescue movement, motor learning, and also depression-like behavior in PD mice,” Zhang says.

Parkinson’s patients are usually treated with L-dopa, a precursor of dopamine. While this drug helps patients regain motor control, it doesn’t help with motor learning or any nonmotor symptoms, and over time, patients become resistant to it.

The researchers hope that the circuits they characterized in this study could be targets for new Parkinson’s therapies. The types of neurons that they identified in the circuits of the mouse brain are also found in the nonhuman primate brain, and the researchers are now using RNA sequencing to find genes that are expressed specifically in those cells.

“RNA-sequencing technology will allow us to do a much more detailed molecular analysis in a cell-type specific way,” Feng says. “There may be better druggable targets in these cells, and once you know the specific cell types you want to modulate, you can identify all kinds of potential targets in them.”

The research was funded, in part, by the K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics in Neuroscience at MIT, the Stanley Center for Psychiatric Research at the Broad Institute, the James and Patricia Poitras Center for Psychiatric Disorders Research at MIT, the National Institutes of Health BRAIN Initiative, and the National Institute of Mental Health.

New research center focused on brain-body relationship established at MIT

by Julie Pryor |

The inextricable link between our brains and our bodies has been gaining increasing recognition among researchers and clinicians over recent years. Studies have shown that the brain-body pathway is bidirectional — meaning that our mental state can influence our physical health and vice versa. But exactly how the two interact is less clear.

A new research center at MIT, funded by a $38 million gift to the McGovern Institute for Brain Research from philanthropist K. Lisa Yang, aims to unlock this mystery by creating and applying novel tools to explore the multidirectional, multilevel interplay between the brain and other body organ systems. This gift expands Yang’s exceptional philanthropic support of human health and basic science research at MIT over the past five years.

“Lisa Yang’s visionary gift enables MIT scientists and engineers to pioneer revolutionary technologies and undertake rigorous investigations into the brain’s complex relationship with other organ systems,” says MIT President L. Rafael Reif.  “Lisa’s tremendous generosity empowers MIT scientists to make pivotal breakthroughs in brain and biomedical research and, collectively, improve human health on a grand scale.”

The K. Lisa Yang Brain-Body Center will be directed by Polina Anikeeva, professor of materials science and engineering and brain and cognitive sciences at MIT and an associate investigator at the McGovern Institute. The center will harness the power of MIT’s collaborative, interdisciplinary life sciences research and engineering community to focus on complex conditions and diseases affecting both the body and brain, with a goal of unearthing knowledge of biological mechanisms that will lead to promising therapeutic options.

“Under Professor Anikeeva’s brilliant leadership, this wellspring of resources will encourage the very best work of MIT faculty, graduate fellows, and research — and ultimately make a real impact on the lives of many,” Reif adds.

microscope image of gut
Mouse small intestine stained to reveal cell nucleii (blue) and peripheral nerve fibers (red).
Image: Polina Anikeeva, Marie Manthey, Kareena Villalobos

Center goals  

Initial projects in the center will focus on four major lines of research:

  • Gut-Brain: Anikeeva’s group will expand a toolbox of new technologies and apply these tools to examine major neurobiological questions about gut-brain pathways and connections in the context of autism spectrum disorders, Parkinson’s disease, and affective disorders.
  • Aging: CRISPR pioneer Feng Zhang, the James and Patricia Poitras Professor of Neuroscience at MIT and investigator at the McGovern Institute, will lead a group in developing molecular tools for precision epigenomic editing and erasing accumulated “errors” of time, injury, or disease in various types of cells and tissues.
  • Pain: The lab of Fan Wang, investigator at the McGovern Institute and professor of brain and cognitive sciences, will design new tools and imaging methods to study autonomic responses, sympathetic-parasympathetic system balance, and brain-autonomic nervous system interactions, including how pain influences these interactions.
  • Acupuncture: Wang will also collaborate with Hilda (“Scooter”) Holcombe, a veterinarian in MIT’s Division of Comparative Medicine, to advance techniques for documenting changes in brain and peripheral tissues induced by acupuncture in mouse models. If successful, these techniques could lay the groundwork for deeper understandings of the mechanisms of acupuncture, specifically how the treatment stimulates the nervous system and restores function.

A key component of the K. Lisa Yang Brain-Body Center will be a focus on educating and training the brightest young minds who aspire to make true breakthroughs for individuals living with complex and often devastating diseases. A portion of center funding will endow the new K. Lisa Yang Brain-Body Fellows Program, which will support four annual fellowships for MIT graduate students and postdocs working to advance understanding of conditions that affect both the body and brain.

Mens sana in corpore sano

“A phrase I remember reading in secondary school has always stuck with me: ‘mens sana in corpore sano’ — ‘a healthy mind in a healthy body,’” says Lisa Yang, a former investment banker committed to advocacy for individuals with visible and invisible disabilities. “When we look at how stress, nutrition, pain, immunity, and other complex factors impact our health, we truly see how inextricably linked our brains and bodies are. I am eager to help MIT scientists and engineers decode these links and make real headway in creating therapeutic strategies that result in longer, healthier lives.”

“This center marks a once-in-a-lifetime opportunity for labs like mine to conduct bold and risky studies into the complexities of brain-body connections,” says Anikeeva, who works at the intersection of materials science, electronics, and neurobiology. “The K. Lisa Yang Brain-Body Center will offer a pathbreaking, holistic approach that bridges multiple fields of study. I have no doubt that the center will result in revolutionary strides in our understanding of the inextricable bonds between the brain and the body’s peripheral organ systems, and a bold new way of thinking in how we approach human health overall.”

Circuit that focuses attention brings in wide array of inputs

by David Orenstein | Picower Institute |

In a new brain-wide circuit tracing study, scientists at MIT’s Picower Institute for Learning and Memory focused selective attention on a circuit that governs, fittingly enough, selective attention. The comprehensive maps they produced illustrate how broadly the mammalian brain incorporates and integrates information to focus its sensory resources on its goals.

Working in mice, the team traced thousands of inputs into the circuit, a communication loop between the anterior cingulate cortex (ACC) and the lateral posterior (LP) thalamus. In primates the LP is called the pulvinar. Studies in humans and nonhuman primates have indicated that the byplay of these two regions is critical for brain functions like being able to focus on an object of interest in a crowded scene, says study co-lead author Yi Ning Leow, a graduate student in the lab of senior author Mriganka Sur, the Newton Professor in MIT’s Department of Brain and Cognitive Sciences. Research has implicated dysfunction in the circuit in attention-affecting disorders such as autism and attention deficit/hyperactivity disorder.

The new study in the Journal of Comparative Neurology extends what’s known about the circuit by detailing it in mice, Leow says, importantly showing that the mouse circuit is closely analogous to the primate version even if the LP is proportionately smaller and less evolved than the pulvinar.

“In these rodent models we were able to find very similar circuits,” Leow says. “So we can possibly study these higher-order functions in mice as well. We have a lot more genetic tools in mice so we are better able to look at this circuit.”

The study, also co-led by former MIT undergraduate Blake Zhou, therefore provides a detailed roadmap in the experimentally accessible mouse model for understanding how the ACC and LP cooperate to produce selective attention. For instance, now that Leow and Zhou have located all the inputs that are wired into the circuit, Leow is tapping into those feeds to eavesdrop on the information they are carrying. Meanwhile, she is correlating that information flow with behavior.

“This study lays the groundwork for understanding one of the most important, yet most elusive, components of brain function, namely our ability to selectively attend to one thing out of several, as well as switch attention,” Sur says.

Using virally mediated circuit-tracing techniques pioneered by co-author Ian Wickersham, principal research scientist in brain and cognitive sciences and the McGovern Institute for Brain Research at MIT, the team found distinct sources of input for the ACC and the LP. Generally speaking, the detailed study finds that the majority of inputs to the ACC were from frontal cortex areas that typically govern goal-directed planning, and from higher visual areas. The bulk of inputs to the LP, meanwhile, were from deeper regions capable of providing context such as the mouse’s needs, location and spatial cues, information about movement, and general information from a mix of senses.

So even though focusing attention might seem like a matter of controlling the senses, Leow says, the circuit pulls in a lot of other information as well.

“We’re seeing that it’s not just sensory — there are so many inputs that are coming from non-sensory areas as well, both sub-cortically and cortically,” she says. “It seems to be integrating a lot of different aspects that might relate to the behavioral state of the animal at a given time. It provides a way to provide a lot of internal and special context for that sensory information.”

Given the distinct sets of inputs to each region, the ACC may be tasked with focusing attention on a desired object, while the LP is modulating how the ACC goes about making those computations, accounting for what’s going on both inside and outside the animal. Decoding just what that incoming contextual information is, and what the LP tells the ACC, are the key next steps, Leow says. Another clear set of questions the study raises are what are the circuit’s outputs. In other words, after it integrates all this information, what does it do with it?

The paper’s other authors are Heather Sullivan and Alexandria Barlowe.

A National Science Scholarship, the National Institutes of Health, and the JPB Foundation provided support for the study.

Aging Brain Initiative awards fund five new ideas to study, fight neurodegeneration

Anne Trafton |

Neurodegenerative diseases are defined by an increasingly widespread and debilitating death of nervous system cells, but they also share other grim characteristics: Their cause is rarely discernible and they have all eluded cures. To spur fresh, promising approaches and to encourage new experts and expertise to join the field, MIT’s Aging Brain Initiative (ABI) this month awarded five seed grants after a competition among labs across the Institute.

Founded in 2015 by nine MIT faculty members, the ABI promotes research, symposia, and related activities to advance fundamental insights that can lead to clinical progress against neurodegenerative conditions, such as Alzheimer’s disease, with an age-related onset. With an emphasis on spurring research at an early stage before it is established enough to earn more traditional funding, the ABI derives support from philanthropic gifts.

“Solving the mysteries of how health declines in the aging brain and turning that knowledge into effective tools, treatments, and technologies is of the utmost urgency given the millions of people around the world who suffer with no meaningful treatment options,” says ABI director and co-founder Li-Huei Tsai, the Picower Professor of Neuroscience in The Picower Institute for Learning and Memory and the Department of Brain and Cognitive Sciences. “We were very pleased that many groups across MIT were eager to contribute their expertise and creativity to that goal. From here, five teams will be able to begin testing their innovative ideas and the impact they could have.”

To address the clinical challenge of accurately assessing cognitive decline during Alzheimer’s disease progression and healthy aging, a team led by Thomas Heldt, associate professor of electrical and biomedical engineering in the Department of Electrical Engineering and Computer Science (EECS) and the Institute for Medical Engineering and Science, proposes to use artificial intelligence tools to bring diagnostics based on eye movements during cognitive tasks to everyday consumer electronics such as smartphones and tablets. By moving these capabilities to common at-home platforms, the team, which also includes EECS Associate Professor Vivian Sze, hopes to increase monitoring beyond what can only be intermittently achieved with high-end specialized equipment and dedicated staffing in specialists’ offices. The team will pilot their technology in a small study at Boston Medical Center in collaboration with neurosurgeon James Holsapple.

Institute Professor Ann Graybiel’s lab in the Department of Brain and Cognitive Sciences (BCS) and the McGovern Institute for Brain Research will test the hypothesis that mutations on a specific gene may lead to the early emergence of Alzheimer’s disease (AD) pathology in the striatum. That’s a a brain region crucial for motivation and movement that is directly and severely impacted by other neurodegenerative disorders including Parkinson’s and Huntington’s diseases, but that has largely been unstudied in Alzheimer’s. By editing the mutations into normal and AD-modeling mice, Research Scientist Ayano Matsushima and Graybiel hope to determine whether and how pathology, such as the accumulation of amyloid proteins, may result. Determining that could provide new insight into the progression of disease and introduce a new biomarker in a region that virtually all other studies have overlooked.

Numerous recent studies have highlighted a potential role for immune inflammation in Alzheimer’s disease. A team led by Gloria Choi, the Mark Hyman Jr. Associate Professor in BCS and The Picower Institute for Learning and Memory, will track one potential source of such activity by determining whether the brain’s meninges, which envelop the brain, becomes a means for immune cells activated by gut bacteria to circulate near the brain, where they may release signaling molecules that promote Alzheimer’s pathology. Working in mice, Choi’s lab will test whether such activity is prone to increase in Alzheimer’s and whether it contributes to disease.

A collaboration led by Peter Dedon, the Singapore Professor in MIT’s Department of Biological Engineering, will explore whether Alzheimer’s pathology is driven by dysregulation of transfer RNAs (tRNAs) and the dozens of natural tRNA modifications in the epitranscriptome, which play a key role in the process by which proteins are assembled based on genetic instructions. With Benjamin Wolozin of Boston University, Sherif Rashad of Tohoku University in Japan, and Thomas Begley of the State University of New York at Albany, Dedon will assess how the tRNA pool and epitranscriptome may differ in Alzheimer’s model mice and whether genetic instructions mistranslated because of tRNA dysregulation play a role in Alzheimer’s disease.

With her seed grant, Ritu Raman, the d’Arbeloff Assistant Professor of Mechanical Engineering, is launching an investigation of possible disruption of intercellular messages in amyotrophic lateral sclerosis (ALS), a terminal condition in which motor neuron causes loss of muscle control. Equipped with a new tool to finely sample interstitial fluid within tissues, Raman’s team will be able to monitor and compare cell-cell signaling in models of the junction between nerve and muscle. These models will be engineered from stem cells derived from patients with ALS. By studying biochemical signaling at the junction the lab hopes to discover new targets that could be therapeutically modified.

Major support for the seed grants, which provide each lab with $100,000, came from generous gifts by David Emmes SM ’76; Kathleen SM ’77, PhD ’86 and Miguel Octavio; the Estate of Margaret A. Ridge-Pappis, wife of the late James Pappis ScD ’59; the Marc Haas Foundation; and the family of former MIT President Paul Gray ’54, SM ’55, ScD ‘60, with additional funding from many annual fund donors to the Aging Brain Initiative Fund.

Developing brain needs cannabinoid receptors after birth

by Jennifer Michalowski |

Doctors warn that marijuana use during pregnancy may have harmful effects on the development of a fetus, in part because the cannabinoid receptors activated by the drug are known be critical for enabling a developing brain to wire up properly. Now, scientists at MIT’s McGovern Institute have learned that cannabinoid receptors’ critical role in brain development does not end at birth.

In today’s online issue of the journal eNeuro, scientists led by McGovern investigator Ann Graybiel report that mice need the cannabinoid receptor CB1R to establish connections within the brain’s dopamine system that take shape soon after birth. The finding raises concern that marijuana use by nursing moms, who pass the CB1R-activating compound THC to their infants when they breastfeed, might interfere with brain development by disrupting cannabinoid signaling.

“This is a real change to one of the truly important systems in the brain—a major controller of our dopamine,” Graybiel says. Dopamine exerts a powerful influence over our motivations and behavior, and changes to the dopamine system contribute to disorders from Parkinson’s disease to addiction. Thus, the researchers say, it is vital to understand whether postnatal drug exposure might put developing dopamine circuits at risk.

Brain bouquets

Cannabinoid receptors in the brain are important mediators of mood, memory, and pain. Graybiel’s lab became interested in CB1R due to their dysregulation in Huntington’s and Parkinson’s diseases, both of which impair the brain’s ability to control movement and other functions. While investigating the receptor’s distribution in the brain, they discovered that in the adult mice, CB1R is abundant within small compartments within the striatum called striosomes. The receptor was particularly concentrated within the neurons that connect striosomes to a dopamine-rich area of the brain called the substantia nigra, via structures that Graybiel’s team has dubbed striosome-dendron bouquets.

Striosome-dendron bouquets are easy to overlook within the densely connected network of the brain. But when the cells that make up the bouquets are labeled with a fluorescent protein, the bouquets become visible—and their appearance is striking, says Jill Crittenden, a research scientist in Graybiel’s lab.

Striosomal neurons form these bouquets by reaching into the substantia nigra, whose cells use dopamine to influence movement, motivation, learning, and habit formation. Clusters of dopamine-producing neurons form dendrites there that intertwine tightly with incoming axons from the striosomal neurons. The resulting structures, whose intimately associated cells resemble the bundled stems of a floral bouquet, establish so many connections that they give striosomal neurons potent control over dopamine signaling.

By tracking the bouquets’ emergence in newborn mice, Graybiel’s team found that they form in the first week after birth, a period during which striosomal neurons are ramping up production of CB1R. Mice genetically engineered to lack CB1R, however, can’t make these elaborate but orderly bouquets. Without the receptor, fibers from striosomes extend into the substantia nigra, but fail to form the tightly intertwined “bouquet stems” that facilitate extensive connections with their targets. This disorganized structure is apparent as soon as bouquets arise in the brains of young pups and persists into adulthood. “There aren’t those beautiful, strong fibers anymore,” Crittenden says. “This suggests that those very strong controllers over the dopamine system function abnormally when you interfere with cannabinoid signaling.”

The finding was a surprise. Without zeroing in on striosome-dendron bouquets, it would be easy to miss CB1R’s impact on the dopamine system, Crittenden says. Plus, she adds, prior studies of the receptor’s role in development largely focused on fetal development. The new findings reveal that the cannabinoid system continues to guide the formation of brain circuits after birth.

Graybiel notes that funds from generous donors, including the Broderick Fund for Phytocannabinoid Research at MIT, the Saks Kavanaugh Foundation, the Kristin R. Pressman and Jessica J. Pourian ‘13 Fund, Mr. Robert Buxton, and the William N. & Bernice E. Bumpus Foundation, enabled her team’s studies of CB1R’s role in shaping striosome-dendron bouquets.

Now that they have shown that CB1R is needed for postnatal brain development, it will be important to determine the consequences of disrupting cannabinoid signaling during this critical period—including whether passing THC to a nursing baby impacts the brain’s dopamine system.

Study finds neurons that encode the outcomes of actions

Anne Trafton |

When we make complex decisions, we have to take many factors into account. Some choices have a high payoff but carry potential risks; others are lower risk but may have a lower reward associated with them.

A new study from MIT sheds light on the part of the brain that helps us make these types of decisions. The research team found a group of neurons in the brain’s striatum that encodes information about the potential outcomes of different decisions. These cells become particularly active when a behavior leads a different outcome than what was expected, which the researchers believe helps the brain adapt to changing circumstances.

“A lot of this brain activity deals with surprising outcomes, because if an outcome is expected, there’s really nothing to be learned. What we see is that there’s a strong encoding of both unexpected rewards and unexpected negative outcomes,” says Bernard Bloem, a former MIT postdoc and one of the lead authors of the new study.

Impairments in this kind of decision-making are a hallmark of many neuropsychiatric disorders, especially anxiety and depression. The new findings suggest that slight disturbances in the activity of these striatal neurons could swing the brain into making impulsive decisions or becoming paralyzed with indecision, the researchers say.

Rafiq Huda, a former MIT postdoc, is also a lead author of the paper, which appears in Nature Communications. Ann Graybiel, an MIT Institute Professor and member of MIT’s McGovern Institute for Brain Research, is the senior author of the study.

Learning from experience

The striatum, located deep within the brain, is known to play a key role in making decisions that require evaluating outcomes of a particular action. In this study, the researchers wanted to learn more about the neural basis of how the brain makes cost-benefit decisions, in which a behavior can have a mixture of positive and negative outcomes.

Striosomes (red) appear and then disappear as the view moves deeper into the striatum. Video courtesy of the researchers

To study this kind of decision-making, the researchers trained mice to spin a wheel to the left or the right. With each turn, they would receive a combination of reward (sugary water) and negative outcome (a small puff of air). As the mice performed the task, they learned to maximize the delivery of rewards and to minimize the delivery of air puffs. However, over hundreds of trials, the researchers frequently changed the probabilities of getting the reward or the puff of air, so the mice would need to adjust their behavior.

As the mice learned to make these adjustments, the researchers recorded the activity of neurons in the striatum. They had expected to find neuronal activity that reflects which actions are good and need to be repeated, or bad and that need to be avoided. While some neurons did this, the researchers also found, to their surprise, that many neurons encoded details about the relationship between the actions and both types of outcomes.

The researchers found that these neurons responded more strongly when a behavior resulted in an unexpected outcome, that is, when turning the wheel in one direction produced the opposite outcome as it had in previous trials. These “error signals” for reward and penalty seem to help the brain figure out that it’s time to change tactics.

Most of the neurons that encode these error signals are found in the striosomes — clusters of neurons located in the striatum. Previous work has shown that striosomes send information to many other parts of the brain, including dopamine-producing regions and regions involved in planning movement.

“The striosomes seem to mostly keep track of what the actual outcomes are,” Bloem says. “The decision whether to do an action or not, which essentially requires integrating multiple outcomes, probably happens somewhere downstream in the brain.”

Making judgments

The findings could be relevant not only to mice learning a task, but also to many decisions that people have to make every day as they weigh the risks and benefits of each choice. Eating a big bowl of ice cream after dinner leads to immediate gratification, but it might contribute to weight gain or poor health. Deciding to have carrots instead will make you feel healthier, but you’ll miss out on the enjoyment of the sweet treat.

“From a value perspective, these can be considered equally good,” Bloem says. “What we find is that the striatum also knows why these are good, and it knows what are the benefits and the cost of each. In a way, the activity there reflects much more about the potential outcome than just how likely you are to choose it.”

This type of complex decision-making is often impaired in people with a variety of neuropsychiatric disorders, including anxiety, depression, schizophrenia, obsessive-compulsive disorder, and posttraumatic stress disorder. Drug abuse can also lead to impaired judgment and impulsivity.

“You can imagine that if things are set up this way, it wouldn’t be all that difficult to get mixed up about what is good and what is bad, because there are some neurons that fire when an outcome is good and they also fire when the outcome is bad,” Graybiel says. “Our ability to make our movements or our thoughts in what we call a normal way depends on those distinctions, and if they get blurred, it’s real trouble.”

The new findings suggest that behavioral therapy targeting the stage at which information about potential outcomes is encoded in the brain may help people who suffer from those disorders, the researchers say.

The research was funded by the National Institutes of Health/National Institute of Mental Health, the Saks Kavanaugh Foundation, the William N. and Bernice E. Bumpus Foundation, the Simons Foundation, the Nancy Lurie Marks Family Foundation, the National Eye Institute, the National Institute of Neurological Disease and Stroke, the National Science Foundation, the Simons Foundation Autism Research Initiative, and JSPS KAKENHI.

David Ginty named winner of 2022 Scolnick Prize

by Jill Crittenden |

Harvard neurobiologist David Ginty, winner of the 2022 Scolnick Prize.

The McGovern Institute for Brain Research announced today that Harvard neurobiologist David D. Ginty has been selected for the 2022 Edward M. Scolnick Prize in Neuroscience. Ginty, who is the Edward R. and Anne G. Lefler Professor of Neurobiology at Harvard Medical School, is being recognized for his fundamental discoveries into the neural mechanisms underlying the sense of touch. The Scolnick Prize is awarded annually by the McGovern Institute for outstanding advances in neuroscience.

“David Ginty has made seminal contributions in basic research that also have important translational implications,” says Robert Desimone, McGovern Institute Director and chair of the selection committee. “His rigorous research has led us to understand how the peripheral nervous system encodes the overall perception of touch, and how molecular mechanisms underlying this can fail in disease states.”

Ginty obtained his PhD in 1989 with Edward Seidel where he studied cell proliferation factors. He went on to a postdoctoral fellowship researching nerve growth factor with John Wagner at the Dana-Farber Cancer Institute and, upon Wagner’s departure to Cornell, transferred to Michael Greenberg’s lab at Harvard Medical School. There, he dissected intracellular signaling pathways for neuronal growth factors and neurotransmitters and developed key antibody reagents to detect activated forms of transcription factors. These antibody tools are now used by labs around the world in the research of neuronal plasticity and brain disorders, including Alzheimer’s disease and schizophrenia.

In 1995, Ginty started his own laboratory at Johns Hopkins University with a focus on the development and functional organization of the peripheral nervous system. Ginty’s group created and applied the latest genetic engineering techniques in mice to uncover how the peripheral nervous system develops and is organized at the molecular, cellular and circuit levels to perceive touch. Most notably, using gene targeting combined with electrophysiological, behavioral and anatomical analyses, the Ginty lab untangled properties and functions of the different types of touch neurons, termed low- and high-threshold mechanoreceptors, that convey distinct aspects of stimulus information from the skin to the central nervous system. Ginty and colleagues also discovered organizational principles of spinal cord and brainstem circuits dedicated to touch information processing, and that integration of signals from the different mechanoreceptor types begins within spinal cord networks before signal transmission to the brain.

In 2013, Ginty joined the faculty of Harvard Medical School where his team applied their genetic tools and techniques to probe the neural basis of touch sensitivity disorders. They discovered properties and functions of peripheral sensory neurons, spinal cord circuits, and ascending pathways that transmit noxious, painful stimuli from the periphery to the brain. They also asked whether abnormalities in peripheral nervous system function lead to touch over-reactivity in cases of autism or in neuropathic pain caused by nerve injury, chemotherapy, or diabetes, where even a soft touch can be aversive or painful. His team found that sensory abnormalities observed in several mouse models of autism spectrum disorder could be traced to peripheral mechanosensory neurons. They also found that reducing the activity of peripheral sensory neurons prevented tactile over-reactivity in these models and even, in some cases, lessened anxiety and abnormal social behaviors. These findings provided a plausible explanation for how sensory dysfunction may contribute to physiological and cognitive impairments in autism. Importantly, this laid the groundwork for a new approach and initiative to identify new potential therapies for disorders of touch and pain.

Ginty was named a Howard Hughes Medical Institute Investigator in 2000 and was elected to the American Academy of Arts and Sciences in 2015 and the National Academy of Sciences in 2017. He shared Columbia University’s Alden W. Spencer Prize with Ardem Patapoutian in 2017 and was awarded the Society for Neuroscience Julius Axelrod Prize in 2021. Ginty is also known for exceptional mentorship. He directed the neuroscience graduate program at Johns Hopkins from 2006 to 2013 and now serves as the associate director of Harvard’s neurobiology graduate program.

The McGovern Institute will award the Scolnick Prize to Ginty on Wednesday, June 1, 2022. At 4:00 pm he will deliver a lecture entitled “The sensory neurons of touch: beauty is skin deep,” to be followed by a reception at the McGovern Institute, 43 Vassar Street (building 46, room 3002) in Cambridge. The event is free and open to the public; registration is required.